Clinical Mass Spectrometry in IVD: PPGL Diagnosis
This article reviews the "Consensus of Multispecialty Experts on Clinical Screening for Secondary Hypertension in China" and the "Expert Consensus on the Diagnosis and Treatment of Pheochromocytoma and Paraganglioma (2020 Edition)" to provide an in-depth understanding of PPGL clinical diagnosis.
I. Clinical Manifestations of PPGL
1. Hypertension
Hypertension is the primary clinical manifestation in PPGL patients, with an incidence rate of 90% to 100%.
2. The Classic Triad
The classic triad observed during hypertensive episodes in PPGL patients is of significant diagnostic importance, occurring in 40% to 48% of patients:
Headache
59% - 71%
Palpitations
50% - 65%
Diaphoresis
50% - 65%
3. Other Clinical Manifestations
| System/Organ | Clinical Manifestations |
|---|---|
| Cardiovascular System | Palpitations, chest tightness, feeling of impending doom, arrhythmia, cardiomyopathy, angina pectoris, myocardial infarction, ventricular hypertrophy, and heart failure |
| Nervous System | Headache, insomnia, irritability, nervous anxiety (20%-40%), coldness of extremities (23%-40%), blurred vision, cerebrovascular accident, disturbance of consciousness |
| Digestive System | Nausea/vomiting (23%-43%), abdominal pain, constipation, intestinal obstruction, cholelithiasis |
| Endocrine & Metabolic | Carbohydrate and lipid metabolic disorders, impaired glucose tolerance or diabetes mellitus (42%-58%), hyperhidrosis, increased metabolic rate, and weight loss (23%-70%) |
II. PPGL Screening Recommendations
Strongly Recommended for (Strong Recommendation | High-Quality Evidence):
- Patients with clinical symptoms and signs: paroxysmal hypertension accompanied by the classic triad of headache, palpitations, and diaphoresis, and/or orthostatic hypotension
- Drug-induced symptom onset: patients whose PPGL symptoms are triggered by certain medications (dopamine receptor antagonists, sympathomimetic agents, opioids, etc.)
- Adrenal incidentaloma: patients found to have an adrenal mass on imaging
- Family history: individuals with a family history of PPGL or PPGL-associated hereditary syndromes
- Prior history: patients with a known prior history of PPGL
III. PPGL-Related Genetic Syndromes
| Gene | Syndrome | Inheritance | Key Features |
|---|---|---|---|
| VHL | VHL Syndrome | AD | Hemangioblastoma, Renal cell carcinoma |
| RET | MEN2 | AD | 100% MTC, Hyperparathyroidism |
| NF1 | Neurofibromatosis Type 1 | AD | 100% NF1, café-au-lait spots |
| SDHB/SDHD | PGL Syndrome | AD | Paraganglioma, GIST |
IV. Qualitative Diagnosis: LC-MS/MS
2020 PPGL Consensus Recommendations (Strong Recommendation | High-Quality Evidence):
- First-line diagnostic test: Measurement of plasma free or urinary concentrations of Metanephrines (MNs)
- Recommended methodology: Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
- Concurrent measurement of norepinephrine, epinephrine, dopamine, and 3-Methoxytyramine (3-MT) aids in diagnosis
- Plasma has higher diagnostic efficacy than urine and better meets the needs for outpatient screening
V. VirtueDX Technical Advantage
Catecholamines and Metabolites Detection Kit
Technical Challenge: The in-vivo content of 3-MT is extremely low. Even with standard LC-MS/MS methods, accurate detection can be challenging due to technical limitations and inherent instrument sensitivity issues.
VirtueDX Solution:
- Non-derivatization method for simplified workflow
- Simultaneous detection of six indicators with a single injection
- LOD for 3-MT as low as 5 pg/ml
- Used in conjunction with QSight 420MD system
